NeuroOne Medical Technologies Corporation reports that it has regained compliance with Nasdaq’s minimum bid price requirement. The company previously received a deficiency letter on May 6, 2025 after its common stock closed below $1.00 per share for 30 consecutive business days.
On April 30, 2026, Nasdaq notified NeuroOne that the closing bid price of its common stock had been at least $1.00 per share for 10 consecutive business days. As a result, Nasdaq considers the company back in compliance with Nasdaq Listing Rule 5550(a)(2), and the bid price matter is closed.
NeuroOne Medical Technologies announced a planned chief financial officer transition. Ronald McClurg intends to retire as CFO effective June 30, 2026, and will remain with the company as a Senior Advisor until December 31, 2026 to support an orderly handover.
Chief Operating Officer Christopher Volker will become CFO on July 1, 2026. The company highlights his prior senior roles at Abbott, Cardiovascular Systems and St. Jude Medical, as well as investment banking experience in healthcare and technology.
Volker’s base salary will increase to $350,000 with other key employment terms unchanged. NeuroOne and McClurg entered into a Transition and Release Agreement under which he continues current salary and benefits through his Retirement Date in exchange for a general release of claims and customary restrictive covenants.
NeuroOne Medical Technologies Corporation Schedule 13G reports that Brian Pratt and Barbara Pratt each beneficially own 627,344 shares of Common Stock, representing 7.4% of the class. The percentage is computed on 8,420,999 shares outstanding following a 1-for-6 reverse stock split of 50,525,995 shares effective April 15, 2026.
The shares are held in a joint account between each Reporting Person and their spouse; shared voting and dispositive power are reported for each at 627,344 shares. The filing includes a joint filing agreement dated April 21, 2026.
NeuroOne Medical Technologies Corporation is enacting a 1-for-6 reverse stock split of its common stock. Every 6 existing shares will be reclassified into 1 new share, with no change to the total number of authorized shares or the $0.001 par value.
The split becomes effective at 5:00 p.m. Eastern Time on April 15, 2026, and NeuroOne’s stock will begin trading on a split-adjusted basis on April 16, 2026 under the symbol NMTC. Fractional share positions will not be issued; instead, affected stockholders will receive a cash payment equal to the market value of the fractional share. Equity incentive plan awards, options and warrants will be proportionally adjusted, and the company notes the reverse split may help it regain compliance with Nasdaq’s minimum bid price requirement.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jason Richard Mills reported equity compensation awards. He received options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments.
He also received a grant of 41,929 restricted stock units that vest in 12 equal monthly installments over one year, with vesting at the end of each month. Following the stock grant, he holds 49,687 shares of common stock directly.
NEUROONE MEDICAL TECHNOLOGIES Corp director Jeffrey S. Mathiesen received new equity compensation. On April 3, 2026, he was granted options to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036. These options vest in 12 equal monthly installments over one year.
On the same date, he also received 41,929 restricted stock units, which vest in 12 equal monthly installments over one year at the end of each month. Following these grants, he directly owns 156,343 shares of common stock. Both grants are compensation awards rather than open-market purchases.
NeuroOne Medical Technologies director Paul Buckman received new equity awards as compensation. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He was also granted 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at the end of each month. Following these awards, he directly holds 178,733 shares of common stock. These are grants, not open-market purchases.
NeuroOne Medical Technologies board member Edward Andrle reported receiving new equity awards. He was granted an option to purchase 26,036 shares of common stock at an exercise price of $0.795 per share, expiring on April 2, 2036, vesting in 12 equal monthly installments over one year.
He also received 41,929 restricted stock units that vest in 12 equal monthly installments over the same one-year period, with vesting at each month-end. Following the stock grant, Andrle directly holds 133,932 shares of common stock.
NeuroOne Medical Technologies Corporation held its annual stockholder meeting and approved several key proposals, including a potential reverse stock split and changes to its equity incentive plan. Stockholders authorized the Board to implement a reverse stock split in a range from 1-for-2 to 1-for-15 of the outstanding common stock.
Two Class III directors, Jeffrey Mathiesen and Edward Andrle, were elected to three-year terms ending at the 2029 annual meeting. Stockholders also ratified Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2026, and approved an amendment to the 2025 Equity Incentive Plan. A total of 30,272,834 shares, representing approximately 59.72% of shares outstanding as of the record date, were present in person or by proxy.
NeuroOne Medical Technologies officer Mark Christianson reported recent transactions in the company’s Common Stock. On March 30, he completed an open-market sale of 15,363 shares at $0.74 per share. On March 31, an additional 253 shares were disposed of as a tax-withholding transaction, covering tax obligations rather than representing a market trade.
Following these transactions, Christianson holds 198,667 shares of NeuroOne Common Stock directly, according to the filing. The activity reflects a net reduction in his position, primarily driven by the open-market sale, with the smaller tax-withholding disposition tied to equity-related compensation.